U.S., Jan. 24 -- ClinicalTrials.gov registry received information related to the study (NCT07361497) titled 'A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)' on Jan. 21.
Brief Summary: A study to evaluate Pumitamig versus Durvalumab following concurrent chemoradiation therapy in participants with unresectable stage III Non-small Cell Lung Cancer (NSCLC)
Study Start Date: April 09, 2026
Study Type: INTERVENTIONAL
Condition:
Non-small Cell Lung Cancer (NSCLC)
Intervention:
DRUG: Pumitamig
Specified dose on specified days
DRUG: Durvalumab
Specified dose on specified days
Recruitment Status: NO...